Prothena Corp. said its Parkinson's disease treatment showed the ability to safely reduce a key protein potentially linked to the disease, in an early stage study.

The treatment, known as PRX002, is one of a new class of drugs known as immunotherapies, which use the bodyâ€™s immune system to fight diseases. Prothera is joining with Roche to...